1-20 of 5662 Search Results for

agent

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
10.1159/000380972
EISBN: 978-3-318-05465-1
... Abstract Approximately 5-10% of patients with end-stage renal disease (ESRD) exhibit hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), defined as a continued need for higher than 300 IU/kg/week doses of epoetin or a 1.5 mg/kg/week dose of darbepoetin. ESA hyporesponsiveness...
Book Chapter
Series: Progress in Respiratory Research
Volume: 39
Published: 31 August 2010
10.1159/000320829
EISBN: 978-3-8055-9567-4
... antifibrotic agents. Our initial lead program, PRM-151, will beneficially affect the outcome of fibrotic disease by temporarily increasing the concentration of circulating SAP. The result will be to decrease the activation of circulating fibrocyte precursors and potentially shift the M2/M1 macrophage...
Book Chapter
Series: Monographs in Virology
Volume: 22
Published: 01 November 2001
10.1159/000061719
EISBN: 978-3-318-00723-7
Book Chapter
Book Chapter
Series: Contributions to Nephrology
Volume: 127
Published: 27 October 1999
10.1159/000059985
EISBN: 978-3-318-00454-0
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter
Book Chapter